Skip to main content

Kåre Schultz

Director and President and Chief Executive Officer

With his leadership positions in various healthcare corporations, including his experience as a chairman and a director of several international corporations and his service as the President and Chief Executive Officer of Teva, Mr. Schultz provides unique global perspective on the healthcare and pharmaceutical industries.

Mr. Schultz became Teva’s President and CEO and a member of the Board of Directors on November 1, 2017.

From May 2015 to October 2017, Mr. Schultz served as President and Chief Executive Officer of H. Lundbeck A/S.

Prior to that, Mr. Schultz worked for nearly three decades at Novo Nordisk, where he served in a number of leadership roles, including Chief Operating Officer, Vice President of Product Supply and Director of Product Planning and Customer Services in the Diabetes Care Division. Mr. Schultz has also held positions at McKinsey and Anderson Consulting.

Mr. Schultz has served as a member of the Board of Directors of LEGO A/S since 2007. From 2010 to 2017, he served as Chairman of the Board of Directors of Royal Unibrew A/S and during 2017 he served on the Board of Directors of Bitten og Mads Clausens Fond, the holding vehicle for Danfoss A/S. Mr. Schultz received a master’s degree in economics from the University of Copenhagen.


Dr. Sol J. Barer

Chairman of the Board Independent Director

Read more

Rosemary A. Crane

Independent Director

Read more

Amir Elstein

Independent Director

Read more

Janet S. Vergis

Independent Director

Read more

Jean-Michel Halfon

Independent Director

Read more

Roberto A. Mignone

Independent Director

Read more

Dr. Perry D. Nisen

Independent Director

Read more

Nechemia (Chemi) J. Peres

Independent Director

Read more

Prof. Ronit Satchi-Fainaro

Independent Director

Read more

Gerald M. Lieberman

Independent Director

Read more